Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer-Reference-Cited by-同舟云学术

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer

Published:2021-01-06 Issue:4 Volume:15 Page:887-900
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Frigola Joan¹,Navarro Alejandro²,Carbonell Caterina¹,Callejo Ana²,Iranzo Patricia²,Cedrés Susana²,Martinez‐Marti Alex²,Pardo Nuria²,Saoudi‐Gonzalez Nadia²,Martinez Debora³⁴,Jimenez Jose⁵,Sansano Irene⁶,Mancuso Francesco M.⁷,Nuciforo Paolo⁵,Montuenga Luis M.⁸⁹¹⁰¹¹,Sánchez‐Cespedes Montse¹²,Prat Aleix³⁴,Vivancos Ana⁷,Felip Enriqueta¹²,Amat Ramon¹^ORCID

Affiliation:

1. Thoracic Cancers Translational Genomics UnitHebron Institute of Oncology (VHIO) Vall d Barcelona Spain

2. Oncology Department Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology (VHIO) Barcelona Spain

3. Department of Medical Oncology Hospital Clinic Barcelona Spain

4. Translational Genomics and Targeted Therapies in Solid Tumors IDIBAPS Barcelona Spain

5. Molecular Oncology GroupVall d'Hebron Institute of Oncology (VHIO) Barcelona Spain

6. Pathology Unit Vall d’Hebron University Hospital Barcelona Spain

7. Cancer Genomics Laboratory Vall d’Hebron Institute of Oncology (VHIO) Barcelona Spain

8. Program in Solid Tumors Center for Applied Medical Research (CIMA) Pamplona Spain

9. Department of Pathology, Anatomy and Physiology School of Medicine University of Navarra Pamplona Spain

10. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid Spain

11. Navarra Health Research Institute (IDISNA) Pamplona Spain

12. Cancer Genetics Group Josep Carreras Leukaemia Research Institute (IJC)Campus ICO‐Germans Trias i Pujol Badalona, Barcelona Spain

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12891

Reference37 articles.

1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

3. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

4. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

5. Tumour-intrinsic resistance to immune checkpoint blockade

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer;Cancer Cell International;2024-06-29

2. Hallmarks of a Genomically Distinct Subclass of Head and Neck Cancer;2024-02-22

3. Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases;OncoImmunology;2023-12-07

4. Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2023-12

5. Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C;Frontiers in Oncology;2023-10-17